.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Johnson and Johnson
Moodys
Covington
Daiichi Sankyo
Argus Health
Colorcon
Cipla
Fuji

Generated: December 17, 2017

DrugPatentWatch Database Preview

Glaxo Grp Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXO GRP LTD, and what generic alternatives to GLAXO GRP LTD drugs are available?

GLAXO GRP LTD has eight approved drugs.

There are thirty US patents protecting GLAXO GRP LTD drugs.

There are five hundred patent family members on GLAXO GRP LTD drugs in fifty-seven countries and twenty-six supplementary protection certificates in fourteen countries.

Summary for Glaxo Grp Ltd

International Patents:500
US Patents:30
Tradenames:13
Ingredients:4
NDAs:8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-003May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-003May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdADVAIR DISKUS 250/50fluticasone propionate; salmeterol xinafoatePOWDER;INHALATION021077-002Aug 24, 2000RXYesYes► Subscribe► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-003May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdZANTAC 150ranitidine hydrochlorideGRANULE, EFFERVESCENT;ORAL020251-002Mar 31, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxo Grp LtdADVAIR HFAfluticasone propionate; salmeterol xinafoateAEROSOL, METERED;INHALATION021254-003Jun 8, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdZANTAC 150ranitidine hydrochlorideTABLET, EFFERVESCENT;ORAL020251-001Mar 31, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Glaxo Grp Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp LtdADVAIR DISKUS 250/50fluticasone propionate; salmeterol xinafoatePOWDER;INHALATION021077-002Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp LtdADVAIR DISKUS 100/50fluticasone propionate; salmeterol xinafoatePOWDER;INHALATION021077-001Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT DISKUS 50fluticasone propionatePOWDER;INHALATION020833-001Sep 29, 2000► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-002May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdZANTAC 300ranitidine hydrochlorideTABLET;ORAL018703-002Dec 9, 1985► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT DISKUS 50fluticasone propionatePOWDER;INHALATION020833-001Sep 29, 2000► Subscribe► Subscribe
Glaxo Grp LtdADVAIR DISKUS 500/50fluticasone propionate; salmeterol xinafoatePOWDER;INHALATION021077-003Aug 24, 2000► Subscribe► Subscribe
Glaxo Grp LtdZANTAC 300ranitidine hydrochlorideTABLET;ORAL018703-002Dec 9, 1985► Subscribe► Subscribe
Glaxo Grp LtdADVAIR HFAfluticasone propionate; salmeterol xinafoateAEROSOL, METERED;INHALATION021254-001Jun 8, 2006► Subscribe► Subscribe
Glaxo Grp LtdADVAIR HFAfluticasone propionate; salmeterol xinafoateAEROSOL, METERED;INHALATION021254-003Jun 8, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GLAXO GRP LTD drugs

Drugname Dosage Strength Tradename Submissiondate
ranitidine hydrochlorideTablets150 mgZANTAC 15010/30/2007

Non-Orange Book Patents for Glaxo Grp Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,144,845Compounds useful in the manufacture of an anti-inflammatory androstane derivative► Subscribe
7,125,985Compounds useful in the manufacture of an anti-inflammatory androstane derivative► Subscribe
6,536,427 Inhalation device► Subscribe
7,531,528Formulation containing anti-inflammatory androstane derivatives► Subscribe
6,858,593 Anti-inflammatory androstane derivative compositions► Subscribe
6,777,399 Anti-inflammatory androstane derivative compositions► Subscribe
8,198,483Phenethanolamine derivatives for treatment of respiratory diseases► Subscribe
2,006,107,948► Subscribe
7,592,329Crystalline complexes of fluticasone-2-furoate► Subscribe
7,982,067Phenethanolamine derivatives for treatment of respiratory diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Glaxo Grp Ltd Drugs

Country Document Number Estimated Expiration
South Africa9711532► Subscribe
Israel162700► Subscribe
China1094876► Subscribe
China1671435► Subscribe
Hungary213221► Subscribe
Ireland910698► Subscribe
Bulgaria107518► Subscribe
Slovakia280967► Subscribe
United Kingdom0403394► Subscribe
Japan2008509766► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Glaxo Grp Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
4 50004-2014Slovakia► SubscribePRODUCT NAME: VILANTEROLTRIFENATAT; REGISTRATION NO/DATE: EU/1/13/886/001 - EU/1/13/886/006 20131113
2008000029Germany► SubscribePRODUCT NAME: FLUTICASONFUROAT UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/07/434/001-003 20080111
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
14/024Ireland► SubscribePRODUCT NAME: VILANTEROL OR A SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
12/2008Austria► SubscribePRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
1425001/02Switzerland► SubscribePRODUCT NAME: VILANTEROL UND FLUTICASON FUROAT; REGISTRATION NO/DATE: SWISSMEDIC 62969 09.01.2014
1305329/01Switzerland► SubscribePRODUCT NAME: FLUTICASON FUROAT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57968 19.12.2007
0140013 00103Estonia► SubscribePRODUCT NAME: VILANTEROOLTRIFENATAAT;REG NO/DATE: K(2013)8089 (LOPLIK) 13.11.2013
2014019,C1425001Lithuania► SubscribePRODUCT NAME: VILANTEROLUM; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Julphar
Citi
Moodys
Queensland Health
Daiichi Sankyo
Johnson and Johnson
Teva
Novartis
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot